Navigation Links
Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
Date:1/7/2008

TAMPA, Fla., Jan. 7 /PRNewswire/ -- Romark Laboratories, L.C., a privately-owned biotechnology company, today announced that Emmet B. Keeffe, M.D., M.A.C.P., has joined the Company as Vice President and Chief Medical Officer.

Most recently, Dr. Keeffe served as Professor of Medicine, Chief of Hepatology and Co-Director of the Liver Transplant Program at Stanford University Medical Center. He is a past-president of the American Gastroenterological Association and the American Society for Gastrointestinal Endoscopy, and served as chair of the Subspecialty Board on Gastroenterology for the American Board of Internal Medicine. He is a Master of the American College of Physicians and a Fellow of the American Gastroenterological Association, the American Society for Gastrointestinal Endoscopy, the American College of Gastroenterology, and the Royal College of Physicians of Ireland.

"Romark's drug discovery research and ongoing clinical development programs offer the promise of new drugs that could change paradigms for treating viral hepatitis," said Dr. Keeffe. "I am excited to have the opportunity to contribute to the advancement of new therapies in this field."

Dr. Keeffe's research interests include antiviral therapy of chronic hepatitis B and C, use of hepatitis vaccines, and liver transplant selection criteria and outcomes. Throughout his career, he has been an active clinical investigator, with a major focus on novel treatment of chronic viral hepatitis and has published more than 500 papers, book chapters and miscellaneous publications. He lectures widely at national and international scientific meetings, and postgraduate courses.

"We are pleased that Dr. Keeffe has chosen to join our Company," said Jean-Francois Rossignol, M.D., Ph.D., Chairman and Chief Science Officer of Romark. "His expertise in the fields of hepatology and gastroenterology will be invaluable as we advance the development of nitazoxanide and other thiazolides
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Free White Paper Helps Biotech Laboratories Maintain a High Level of Infection Control
3. Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB
4. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
5. ARUP Laboratories Releases ARUP Consult(R) 2.0
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
7. Stiefel Laboratories Appoints Two New Members to Board of Directors
8. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
9. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
10. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
11. Codexis Appoints Singapore Laboratories Managing Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... famous for a number of breakthroughs, which altered the ... a paper, which laid the foundation of computer science, ... He next played a pivotal role in the Second ... military codes, enabling the Allies to defeat the Nazis ... he turned his attention to artificial intelligence and proposed ...
(Date:7/31/2014)... 2014 According to a new ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... at USD 88.5 million in 2011, which is expected ... a CAGR of 53.8% from 2013 to 2023. ... http://www.transparencymarketresearch.com/quantum-dots.html Increasing demand for energy efficient ...
(Date:7/31/2014)... DUBLIN , July 31, 2014 ... the "Global Genomics Market 2014-2018" report to ... Genomics is the study of the genetic ... to be a strong basis for the discovery and ... of human diseases or health conditions. Genomics is supported ...
(Date:7/31/2014)... San Francisco, Calif. (PRWEB) July 31, 2014 ... provides newly diagnosed patients with an overview of the ... the management of drug side effects, as well as ... , “We’re grateful to Dr. Sandy Srinivas for organizing ... 25-year survivor of kidney cancer. “Sandy and her colleagues ...
Breaking Biology Technology:A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 4Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... Inc., a privately-,held, specialty pharmaceutical company, announced today ... financing, which included investors Domain Associates,Latterell Venture Partners ... committed to the development of prescription,products based on ... unmet,needs of patients and their caregivers. Meritage Pharma,s ...
... and existing antibiotics to create a broad offering of ... ... LONDON, June 16 Mpex Pharmaceuticals and,GlaxoSmithKline (GSK) today announced ... discovery, development and,commercialization of novel medicines for bacterial diseases. The,collaboration ...
... Medullary Thyroid Cancer Planned to Initiate This Summer, ... Inc. (Nasdaq: EXEL ) announced today that ... (FDA) have reached agreement on the phase 3,registration ... targeting,MET, RET, and VEGFR2, via the Special Protocol ...
Cached Biology Technology:Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing 2GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 2GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 3GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 4GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 5Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 2Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 3Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 4Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 5
(Date:7/31/2014)... Oren Tessler, Assistant Professor of Clinical Surgery at LSU ... part of a team of plastic and reconstructive surgeons ... to screen and select patients for a specific surgical ... who underwent this surgery to decompress the nerves that ... cosmetic eyelid surgery. The study, which confirms the benefit ...
(Date:7/31/2014)... Biometrics industry sees growth as ... companies turn towards digital currency: NXT-ID, Inc. (OTCBB: NXTD), ... (NASDAQ: AMZN ), Facebook Inc. (NASDAQ: ... ) and Microsoft Corporation (NASDAQ: MSFT) NXT-ID, Inc., ... m-commerce market, announces a video featuring its next generation ...
(Date:7/30/2014)... paving the way for a breakthrough that may ... exposed to poisonous chemicalsparticularly those in pesticides and ... current issue of the journal ChemBioChem ... compounds commonly used in pesticides and warfare agents. ... of Engineering Associate Professor of Chemical and Biological ...
Breaking Biology News(10 mins):Surgeons report significant migraine relief from cosmetic eyelid surgery technique 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 3Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 4Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 5Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 6Engineering a protein to prevent brain damage from toxic agents 2
... 6, 2013  Daniel P. Linskey, superintendent-in-chief of the Boston ... Marathon Bombings" at the 2013 IEEE International Conference on Technologies ... Linskey,s talk will focus on the aftermath of the tragic ... department and federal enforcement agencies that ultimately led to the ...
... in the early 1990s, the protein STAT1 (Signal Transducer ... be central in passing signals across immune cells, ensuring ... from viruses or other pathogens. Animals without STAT1 are ... somehow involved in protection against malignant cells. The STAT1 ...
... To protect consumers, screening shellfish for fungal toxins is ... September) in the Society for Applied Microbiology (SfAM) journal, ... an area with contamination by strains of Penicillium ... will contain toxins at much higher levels that are ...
Cached Biology News:Boston Police Chief to Address Boston Marathon Bombings at IEEE Homeland Security Conference in Waltham, Mass., on 12 November 2Static killers? 2
Request Info...
supplied with 10x reaction buffer...
... ATP: D-hexose 6- phosphotransferase/D-glucose-6-phosphate: NADP ... of HK will phosphorylate 1 ... min at 25C at pH ... will oxidize 1 mol of ...
Request Info...
Biology Products: